unasyn 1000:500mg vial powder for solution for injection
pfizer, italy - ampicillin,sulbactam - powder for solution for injection - 1000,500 mg,
unasyn 2000:1000mg vial powder for solution for injection
pfizer - ampicillin, salbactam - powder for solution for injection - 2000 , 1000 mg
unasyn 500:250mg vial powder for solution for injection
pfizer, italy - ampicillin,sulbactam - powder for solution for injection - 250,125 mg,
unasyn 1.5 g polvo para solucion inyectable i.v., i.m.
pfizer italia s.r.l. - sulbactam (sÓdico) - sulbactam (sÓdico)....500 mg / ampicilina (sÓdica)....1000 mg
unasyn tablet
pfizer laboratories limited 197 lenana road - nairobi - sultamicillin tosylate dihydrate - tablet - 375mg - beta-lactamantibacterials: combinations of
unasyn powder for injection
pfizer laboratories limited 197 lenana road - nairobi - ampicillin/sulbactam - powder for injection - 1500mg - beta-lactamantibacterials: combinations of
unasyn fine granules for pediatric use 10% (ユナシン細粒小児用10%)
pfizer pharmaceuticals inc. - sultamicillin tosilate hydrate - pale orange fine granule
prevacid- lansoprazole capsule, delayed release
lake erie medical dba quality care products llc - lansoprazole (unii: 0k5c5t2qpg) (lansoprazole - unii:0k5c5t2qpg) - lansoprazole 30 mg - prevacid is indicated for short-term treatment (for 4 weeks) for healing and symptom relief of active duodenal ulcer [see clinical studies (14)]. triple therapy: prevacid/amoxicillin/clarithromycin prevacid in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate h. pylori. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see clinical studies (14)]. please refer to the full prescribing information for amoxicillin and clarithromycin. dual therapy: prevacid/amoxicillin prevacid in combination with amoxicillin as dual therapy is indicated for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected (see the clarithro
lansoprazole capsule delayed release
bryant ranch prepack - lansoprazole (unii: 0k5c5t2qpg) (lansoprazole - unii:0k5c5t2qpg) - lansoprazole 30 mg
omeprazole- omeprazole capsule, delayed release
lake erie medical dba quality care products llc - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9) - omeprazole 40 mg - omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. most patients heal within four weeks. some patients may require an additional four weeks of therapy. omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with h. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate h. pylori in adults. omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with h. pylori infection and duodenal ulcer disease to eradicate h. pylori in adults. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see clinical studies (14.1) and dosage and administration (2) ]. among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. in p